Table 10 List of the repositioning candidates, therapeutic category and the supporting published evidence in \(\#Cluster_3\)

Bevacizumab

Angiogenesis inhibitors and antibodies

[26]

Minocycline

Anti-bacterial and anti-infective agents

[45]

Gliclazide

Alimentary tract and metabolism

[46]

Carvedilol

Adrenergic agents

[47]

Ranibizumab

Angiogenesis inhibitors and antibodies

–

Tromethamine

Drug delivery systems

[48]

Vandetanib

Antineoplastic agents

–

Veglin

–

–

Denibulin

Heterocyclic compounds

[49]

Foreskin keratinocyte

Allogeneic cultured cell scaffold

[50]